Pancreatic cancer is one of the deadliest cancers. Even with aggressive treatment, the prognosis is poor.
Various factors stack the odds against successful pancreatic cancer treatment:
- Early detection is uncommon. Few pancreatic cancers are found in the early stages of the disease, when the cancerous cells can be surgically removed. Signs and symptoms of pancreatic cancer — such as pain in the upper abdomen, yellow skin and eyes, and weight loss — don't typically occur until the disease is advanced. There are no effective screening tests for pancreatic cancer. If you or your family has a significant history of pancreatic or other cancer, discuss with your doctor whether you should be undergoing any routine checkups.
- Pancreatic cancer tends to spread quickly. The pancreas lies at the junction of several very important structures in your abdomen, making it easy for the cancer to spread into these structures and organs. Pancreatic cancer often spreads to nearby organs — including the liver, gallbladder and intestines — early in the course of the disease.
- Recurrence is likely. Even after surgical removal, pancreatic cancer often recurs.
In addition, pancreatic cancer tends to be relatively resistant to chemotherapy. However, several newer treatments show promise in increasing the response rate to pancreatic cancer treatment.
Nov. 02, 2018
- Fernandez-del Castillo C. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer. http://www.uptodate.com/home. Accessed June 8, 2016.
- Ryan DP, et al. Treatment for potentially resectable exocrine pancreatic cancer. http://www.uptodate.com/home. Accessed July 15, 2016.
- Ryan DP. Chemotherapy for advanced exocrine pancreatic cancer. http://www.uptodate.com/home. Accessed July 18, 2016.
- Can pancreatic cancer be found early? American Cancer Society. http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-detection. Accessed July 18, 2016.
- Ko AH, et al. A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma. Clinical Cancer Research. 2016;22:61.
- Seicean A, et al. New targeted therapies in pancreatic cancer. World Journal of Gastroenterology. 2015;21:6127.
- FDA approval for erlotinib hydrochloride. National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/drugs/fda-erlotinib-hydrochloride. Accessed July 19, 2016.
- Mei L, et al. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: Controversies and promises. Journal of Gastrointestinal Oncology. 2016;7:487.
- Signs and symptoms of pancreatic cancer. American Cancer Society. http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-signs-and-symptoms. Accessed July 19, 2016.
- What is pancreatic cancer? American Cancer Society. http://www.cancer.org/cancer/pancreaticcancer/if-you-have-pancreatic-cancer. Accessed July 19, 2016.
- Moynihan TJ (expert opinion). Mayo Clinic. Rochester, Minn. July 19, 2016.